Company news
Fate Therapeutics, Inc. (NASDAQ:FATE) news
Every Fate Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 ...
September 10, 2026
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 ...
September 9, 2026
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
September 3, 2026
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
August 14, 2026
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 13, 2026
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
July 9, 2026
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ...
July 6, 2026
Fate Therapeutics Appoints Laura Hamill to Board of Directors
June 15, 2026
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
June 4, 2026
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
June 1, 2026
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline f...
May 21, 2026
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 11, 2026
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufac...
May 5, 2026
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline f...
May 4, 2026
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) ...
April 30, 2026
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment...
April 17, 2026
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment...
April 16, 2026
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment...
April 16, 2026
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
April 9, 2026
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
March 3, 2026
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
February 26, 2026
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2026
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythemat...
December 8, 2025
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
November 13, 2025
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients wi...
October 26, 2025
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
October 14, 2025
Fate Therapeutics to Present at Upcoming Investor Conferences
August 25, 2025
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
August 12, 2025
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
July 15, 2025
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-f...
June 11, 2025
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
May 30, 2025
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
May 28, 2025
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
April 29, 2025
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Syste...
April 14, 2025
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 5, 2025
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 4, 2025
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
December 9, 2024
Fate Therapeutics Announces Leadership Transition
November 29, 2024
Fate Therapeutics to Present at Upcoming December Investor Conferences
November 26, 2024
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 18, 2024
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioni...
November 18, 2024
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of A...
November 9, 2024
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annua...
November 8, 2024
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
July 31, 2024